Edition:
United States

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

33.05USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$33.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,624
52-wk High
$39.67
52-wk Low
$15.31

Select another date:

Mon, Mar 19 2018

BRIEF-Albireo Pharma Inc Files For Non-Timely 10-K ‍​

* ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC ‍​ Source text: (http://bit.ly/2pobWiJ) Further company coverage:

BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results

* ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-Albireo Prices $65.0 Mln Public Offering Of Common Stock

* ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS

BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners

* ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN

BRIEF-Albireo posts Q3 loss per share $0.73‍​

* Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​

BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease

* Final results of Albireo’s phase 2 study of A4250 in children with cholestatic liver disease presented at the liver meeting 2017

Select another date: